Evidence map›Paper›PMID 36210251›Full record

ArticleVaccine2022

Predicting the long-term impact of rotavirus vaccination in 112 countries from 2006 to 2034: A transmission modeling analysis.

A N M Kraay, M K Steele, J M Baker, E W Hall, A Deshpande, B F Saidzosa, A Mukaratirwa, A Boula, E M Mpabalwani, N M Kiulia and 13 more

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Estimating the global impact of rotavirus vaccines on child mortality.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 15 institutions in 13 countries.

A N M KraayDepartment of Kinesiology and Community Health, University of Illinois, Champaign, IL, United States; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States. Electronic address: akraay@illinois.edu.
M K SteeleDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States.
J M BakerDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States.
E W HallDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States.
A DeshpandeDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States.
B F SaidzosaState Institution "Republican Center of Immunoprophylaxis" of Ministry of Health and Social Protection of Population of the Republic of Tajikistan, Dushanbe, Tajikistan.
A MukaratirwaMinistry of Health and Child Welfare, Zimbabwe.
A BoulaMother & Child Hospital (MCH), Chantal Biya Foundation, Yaoundé, Cameroon.
E M MpabalwaniUniversity Teaching Hospital, Lusaka, Zambia.
N M KiuliaEnteric Pathogens and Water Research Laboratory, Institute of Primate Research, Karen, Nairobi, Kenya.
E TsolenyanuDepartment of Paediatrics, Medical School of Lome, Togo; Ministry of Health, Togo.
C Enweronu-LaryeaDepartment of Pediatrics, University of Ghana Medical School, Accra, Ghana.
A AbebeEthiopian Public Health Institute, Addis Ababa, Ethiopia.
B BeyeneEthiopian Public Health Institute, Addis Ababa, Ethiopia.
M TeferaEthiopian Public Health Institute, Addis Ababa, Ethiopia.
R WilliloRTI International, Dar es Salaam, Tanzania.
N BatmunkhExpanded Programme on Immunisation, Regional Office for the Western Pacific, World Health Organization, Manila, Philippines.
R PastoreDivision of Country Health Programmes, Vaccine-preventable Diseases and Immunization (VPI), World Health Organization Regional Office for the Europe, Copenhagen, Denmark.
J M MwendaWHO Regional Office for Africa, Immunization and Vaccines Development, Brazzaville, Congo.
S AntoniDepartment of Immunization, Vaccines, and Biologicals, World Health Organization, Geneva, Switzerland.
A L CohenDepartment of Immunization, Vaccines, and Biologicals, World Health Organization, Geneva, Switzerland.
V E PitzerDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University, New Haven, CT, United States.
B A LopmanDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States.
Emory University · USEthiopian Public Health Institute · ETWorld Health Organization · CHCentre International De Reference Chantal Biya · CMIllinois Department of Public Health · USInstitute of Primate Research · KEMinistry of Health and Child Welfare · ZWPlan International Tanzania · TZTogolese Ministry of Health · TGUniversity of Ghana · GHUniversity Teaching Hospital · ZMWorld Health Organization Regional Office for Africa · CGWorld Health Organization Regional Office for Europe · DKWorld Health Organization Regional Office for the Western Pacific · PHYale University · US

Funding

Modeling the impact and cost-effectiveness of next-generation rotavirus vaccine strategies in low- and middle-income countriesR01AI112970 · NIAID · YALE UNIVERSITY · PI PITZER, VIRGINIA E · 2015 to 2024
$4.1M
NIAID NIH HHS R01 AI112970World Health Organization 001
6 · The paper itself

Abstract

Rotavirus vaccination has been shown to reduce rotavirus burden in many countries, but the long-term magnitude of vaccine impacts is unclear, particularly in low-income countries. We use a transmission model to estimate the long-term impact of rotavirus vaccination on deaths and disability adjusted life years (DALYs) from 2006 to 2034 for 112 low- and middle-income countries. We also explore the predicted effectiveness of a one- vs two- dose series and the relative contribution of direct vs indirect effects to overall impacts. To validate the model, we compare predicted percent reductions in severe rotavirus cases with the percent reduction in rotavirus positivity among gastroenteritis hospital admissions for 10 countries with pre- and post-vaccine introduction data. We estimate that vaccination would reduce deaths from rotavirus by 49.1 % (95 % UI: 46.6-54.3 %) by 2034 under realistic coverage scenarios, compared to a scenario without vaccination. Most of this benefit is due to direct benefit to vaccinated individuals (explaining 69-97 % of the overall impact), but indirect protection also appears to enhance impacts. We find that a one-dose schedule would only be about 57 % as effective as a two-dose schedule 12 years after vaccine introduction. Our model closely reproduced observed reductions in rotavirus positivity in the first few years after vaccine introduction in select countries. Rotavirus vaccination is likely to have a substantial impact on rotavirus gastroenteritis and its mortality burden. To sustain this benefit, the complete series of doses is needed.

Indexed as

GastroenteritisRotavirusRotavirus InfectionsRotavirus VaccinesCost-Benefit AnalysisHumansInfantVaccinationRotavirus VaccinesDirect effectsIndirect effectsPartial doseRotarixRotateqRotavirus

Identifiers

PMID36210251
PMCPMC10351612
OpenAlexW4303194625

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.